ℹ️
🇬🇧
Search
Search for publications relevant for "intramuscular interferon"
intramuscular interferon
Publication
Class
Person
Publication
Programmes
publication
Treatment intramuscular interferon beta-1a
2013 |
First Faculty of Medicine
publication
Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
2017 |
First Faculty of Medicine
publication
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
2017 |
First Faculty of Medicine
publication
Early magnetic resonance imaging predictors of clinical progression after 48months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a
2015 |
First Faculty of Medicine
publication
AMETYST - results of an observational phase IV clinical study evaluating the effect of intramuscular interferon beta-1a therapy in patients with clinically isolated syndrome or clinically definite multiple sclerosis
2017 |
First Faculty of Medicine
publication
Intramuscular Interferon beta-1a, Azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy results
Publication without faculty affiliation
publication
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
2018 |
First Faculty of Medicine
publication
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
2012 |
First Faculty of Medicine
publication
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
2012 |
Second Faculty of Medicine
publication
Intramuscular Interferon Beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled study
Publication without faculty affiliation
publication
Intramuscular Interferon Beta-1 in Combination with Azathioprine and Low-Dose Steroids for Relapsing-Remitting Multiple Sclerosis: Design and Preliminary Results of Two-Year Double-Blind, Randomized, Placebo-Controlled Study
Publication without faculty affiliation
publication
Intramuscular Interferon Beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled study
2001 |
Faculty of Physical Education and Sport
publication
Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study
2019 |
Faculty of Medicine in Hradec Králové
publication
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
2015 |
First Faculty of Medicine
publication
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
2012 |
First Faculty of Medicine
publication
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
2015 |
First Faculty of Medicine
publication
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS
2016 |
First Faculty of Medicine
publication
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
2017 |
First Faculty of Medicine
publication
Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome
2015 |
First Faculty of Medicine
publication
Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients
2017 |
First Faculty of Medicine
publication
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
2015 |
First Faculty of Medicine
publication
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later
2016 |
First Faculty of Medicine
publication
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
2019 |
First Faculty of Medicine
publication
Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome
2014 |
First Faculty of Medicine
publication
Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes
2014 |
First Faculty of Medicine
publication
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial
2019 |
First Faculty of Medicine
publication
Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event
2013 |
First Faculty of Medicine
publication
MRI correlates of disability progression in patients with CIS over 48 months
2014 |
First Faculty of Medicine, Faculty of Physical Education and Sport
publication
Pregnancy Experience : Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
2016 |
First Faculty of Medicine
publication
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
2021 |
First Faculty of Medicine